The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer

Jun Yu, Etmar Bulk, Ping Ji, Antje Hascher, Moying Tang, Ralf Metzger, Alessandro Marra, Hubert Serve, Wolfgang E. Berdel, Rainer Wiewroth, Steffen Koschmieder, Carsten Müller-Tidow

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Purpose: Loss of EPHB6 receptor tyrosine kinase expression in early-stage non-small cell lung carcinoma (NSCLC) is associated with the subsequent development of distant metastasis. Here, we analyzed the regulation and function of EPHB6 in lung cancer metastasis. Experimental Design: The expression levels of EPHB6 were compared among normal lung tissue (n = 9), NSCLC without metastasis (n = 39), and NSCLC with metastasis (n = 39) according to the history of the patients. In addition, EPHB6 expression levels of matched tumor-normal pairs from 24 NSCLC patients were analyzed. The promoter DNA methylation status and its association with the expression levels of EPHB6 were determined among 14 pairs of tumor-normal samples. Metastatic potential of EPHB6 was assessed in vitro and in vivo in a metastasis mouse model. Overexpression and RNA interference (RNAi) approaches were used for analysis of the biological functions of EPHB6. Results: EPHB6 mRNA and protein levels were significantly reduced in NSCLC tumors compared with matched normal lung tissue. Decreased EPHB6 expression levels were associated with an increased risk for metastasis development in NSCLC patients. Loss of expression correlated with EPHB6 hypermethylation. EPHB6 expression was induced by 5-aza-2'-deoxycytidine treatment in an NSCLC cell line. Restoration of EPHB6 expression in lung adenocarcinoma cells increased adhesion and decreased migration. Reexpression of EPHB6 in lung cancer cells almost entirely abolished metastasis formation in non obese diabetic (NOD)/severe combined immunodeficient mice. Conclusions: Taken together, these analyses show that EPHB6 is a metastasis inhibitory gene that is frequently silenced by hypermethylation of its promoter in NSCLC.

Original languageEnglish (US)
Pages (from-to)2275-2283
Number of pages9
JournalClinical Cancer Research
Volume16
Issue number8
DOIs
StatePublished - Apr 15 2010
Externally publishedYes

Fingerprint

Receptor Protein-Tyrosine Kinases
Non-Small Cell Lung Carcinoma
Neoplasm Metastasis
DNA
decitabine
Lung Neoplasms
Neoplasms
Lung
SCID Mice
DNA Methylation
RNA Interference
Cell Adhesion
Research Design
History
Cell Line
Messenger RNA
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer. / Yu, Jun; Bulk, Etmar; Ji, Ping; Hascher, Antje; Tang, Moying; Metzger, Ralf; Marra, Alessandro; Serve, Hubert; Berdel, Wolfgang E.; Wiewroth, Rainer; Koschmieder, Steffen; Müller-Tidow, Carsten.

In: Clinical Cancer Research, Vol. 16, No. 8, 15.04.2010, p. 2275-2283.

Research output: Contribution to journalArticle

Yu, J, Bulk, E, Ji, P, Hascher, A, Tang, M, Metzger, R, Marra, A, Serve, H, Berdel, WE, Wiewroth, R, Koschmieder, S & Müller-Tidow, C 2010, 'The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer', Clinical Cancer Research, vol. 16, no. 8, pp. 2275-2283. https://doi.org/10.1158/1078-0432.CCR-09-2000
Yu, Jun ; Bulk, Etmar ; Ji, Ping ; Hascher, Antje ; Tang, Moying ; Metzger, Ralf ; Marra, Alessandro ; Serve, Hubert ; Berdel, Wolfgang E. ; Wiewroth, Rainer ; Koschmieder, Steffen ; Müller-Tidow, Carsten. / The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 8. pp. 2275-2283.
@article{72e524348e03419584df10588063e7cd,
title = "The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer",
abstract = "Purpose: Loss of EPHB6 receptor tyrosine kinase expression in early-stage non-small cell lung carcinoma (NSCLC) is associated with the subsequent development of distant metastasis. Here, we analyzed the regulation and function of EPHB6 in lung cancer metastasis. Experimental Design: The expression levels of EPHB6 were compared among normal lung tissue (n = 9), NSCLC without metastasis (n = 39), and NSCLC with metastasis (n = 39) according to the history of the patients. In addition, EPHB6 expression levels of matched tumor-normal pairs from 24 NSCLC patients were analyzed. The promoter DNA methylation status and its association with the expression levels of EPHB6 were determined among 14 pairs of tumor-normal samples. Metastatic potential of EPHB6 was assessed in vitro and in vivo in a metastasis mouse model. Overexpression and RNA interference (RNAi) approaches were used for analysis of the biological functions of EPHB6. Results: EPHB6 mRNA and protein levels were significantly reduced in NSCLC tumors compared with matched normal lung tissue. Decreased EPHB6 expression levels were associated with an increased risk for metastasis development in NSCLC patients. Loss of expression correlated with EPHB6 hypermethylation. EPHB6 expression was induced by 5-aza-2'-deoxycytidine treatment in an NSCLC cell line. Restoration of EPHB6 expression in lung adenocarcinoma cells increased adhesion and decreased migration. Reexpression of EPHB6 in lung cancer cells almost entirely abolished metastasis formation in non obese diabetic (NOD)/severe combined immunodeficient mice. Conclusions: Taken together, these analyses show that EPHB6 is a metastasis inhibitory gene that is frequently silenced by hypermethylation of its promoter in NSCLC.",
author = "Jun Yu and Etmar Bulk and Ping Ji and Antje Hascher and Moying Tang and Ralf Metzger and Alessandro Marra and Hubert Serve and Berdel, {Wolfgang E.} and Rainer Wiewroth and Steffen Koschmieder and Carsten M{\"u}ller-Tidow",
year = "2010",
month = "4",
day = "15",
doi = "10.1158/1078-0432.CCR-09-2000",
language = "English (US)",
volume = "16",
pages = "2275--2283",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer

AU - Yu, Jun

AU - Bulk, Etmar

AU - Ji, Ping

AU - Hascher, Antje

AU - Tang, Moying

AU - Metzger, Ralf

AU - Marra, Alessandro

AU - Serve, Hubert

AU - Berdel, Wolfgang E.

AU - Wiewroth, Rainer

AU - Koschmieder, Steffen

AU - Müller-Tidow, Carsten

PY - 2010/4/15

Y1 - 2010/4/15

N2 - Purpose: Loss of EPHB6 receptor tyrosine kinase expression in early-stage non-small cell lung carcinoma (NSCLC) is associated with the subsequent development of distant metastasis. Here, we analyzed the regulation and function of EPHB6 in lung cancer metastasis. Experimental Design: The expression levels of EPHB6 were compared among normal lung tissue (n = 9), NSCLC without metastasis (n = 39), and NSCLC with metastasis (n = 39) according to the history of the patients. In addition, EPHB6 expression levels of matched tumor-normal pairs from 24 NSCLC patients were analyzed. The promoter DNA methylation status and its association with the expression levels of EPHB6 were determined among 14 pairs of tumor-normal samples. Metastatic potential of EPHB6 was assessed in vitro and in vivo in a metastasis mouse model. Overexpression and RNA interference (RNAi) approaches were used for analysis of the biological functions of EPHB6. Results: EPHB6 mRNA and protein levels were significantly reduced in NSCLC tumors compared with matched normal lung tissue. Decreased EPHB6 expression levels were associated with an increased risk for metastasis development in NSCLC patients. Loss of expression correlated with EPHB6 hypermethylation. EPHB6 expression was induced by 5-aza-2'-deoxycytidine treatment in an NSCLC cell line. Restoration of EPHB6 expression in lung adenocarcinoma cells increased adhesion and decreased migration. Reexpression of EPHB6 in lung cancer cells almost entirely abolished metastasis formation in non obese diabetic (NOD)/severe combined immunodeficient mice. Conclusions: Taken together, these analyses show that EPHB6 is a metastasis inhibitory gene that is frequently silenced by hypermethylation of its promoter in NSCLC.

AB - Purpose: Loss of EPHB6 receptor tyrosine kinase expression in early-stage non-small cell lung carcinoma (NSCLC) is associated with the subsequent development of distant metastasis. Here, we analyzed the regulation and function of EPHB6 in lung cancer metastasis. Experimental Design: The expression levels of EPHB6 were compared among normal lung tissue (n = 9), NSCLC without metastasis (n = 39), and NSCLC with metastasis (n = 39) according to the history of the patients. In addition, EPHB6 expression levels of matched tumor-normal pairs from 24 NSCLC patients were analyzed. The promoter DNA methylation status and its association with the expression levels of EPHB6 were determined among 14 pairs of tumor-normal samples. Metastatic potential of EPHB6 was assessed in vitro and in vivo in a metastasis mouse model. Overexpression and RNA interference (RNAi) approaches were used for analysis of the biological functions of EPHB6. Results: EPHB6 mRNA and protein levels were significantly reduced in NSCLC tumors compared with matched normal lung tissue. Decreased EPHB6 expression levels were associated with an increased risk for metastasis development in NSCLC patients. Loss of expression correlated with EPHB6 hypermethylation. EPHB6 expression was induced by 5-aza-2'-deoxycytidine treatment in an NSCLC cell line. Restoration of EPHB6 expression in lung adenocarcinoma cells increased adhesion and decreased migration. Reexpression of EPHB6 in lung cancer cells almost entirely abolished metastasis formation in non obese diabetic (NOD)/severe combined immunodeficient mice. Conclusions: Taken together, these analyses show that EPHB6 is a metastasis inhibitory gene that is frequently silenced by hypermethylation of its promoter in NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=77950979765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950979765&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-2000

DO - 10.1158/1078-0432.CCR-09-2000

M3 - Article

VL - 16

SP - 2275

EP - 2283

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -